Literature DB >> 26720825

A Canadian Primary Care Sentinel Surveillance Network Study Evaluating Antidepressant Prescribing in Canada From 2006 to 2012.

Rachael Morkem1, David Barber2, Tyler Williamson3, Scott B Patten4.   

Abstract

OBJECTIVE: To evaluate the prescribing patterns of antidepressants (ADs) by primary care providers to youth, adults, and seniors, from 2006 to 2012, using data from electronic medical records (EMRs).
METHOD: This was a retrospective cross-sectional database study that used primary care data from the Canadian Primary Care Sentinel Surveillance Network (CPCSSN). Data on more than 600 000 Canadian primary care patients were used to determine the prevalence and incidence of AD prescribing to patients 15 years and older who had an encounter in the years of study (from 2006 to 2012). Each study year was evaluated independently.
RESULTS: The study population consisted of 86 927 patients in 2006 (mean age 48.1 years [SD 18.7], 38% male) and grew to 273 529 (mean age 49.6 years [SD 19.3], 40% male) in 2012. The prevalence of AD prescribing increased from 9.20% in 2006 to 12.80% in 2012 (P < 0.001). While the incidence rate of AD prescribing dropped from 3.54% in 2006 to 2.72% in 2008 (P < 0.001) the rate started to significantly rise again, reaching an incidence of 3.07% by 2012 (P < 0.001).
CONCLUSIONS: The prevalence of AD prescribing by primary care providers in Canada continued to rise from 2006 to 2012. Conversely, incidence has remained stable or declined during the 6-year study period. While many complex factors likely contribute to the observed prevalence and incidence rates, our findings suggest that the guidelines indicating the efficacy of long-term AD therapy for patients with highly recurrent or severe depression are being followed.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26720825      PMCID: PMC4679165          DOI: 10.1177/070674371506001207

Source DB:  PubMed          Journal:  Can J Psychiatry        ISSN: 0706-7437            Impact factor:   4.356


  31 in total

1.  Antidepressant utilization in British Columbia from 1996 to 2004: increasing prevalence but not incidence.

Authors:  Colette B Raymond; Steven G Morgan; Patricia A Caetano
Journal:  Psychiatr Serv       Date:  2007-01       Impact factor: 3.084

2.  Proportion of antidepressants prescribed without a psychiatric diagnosis is growing.

Authors:  Ramin Mojtabai; Mark Olfson
Journal:  Health Aff (Millwood)       Date:  2011-08       Impact factor: 6.301

3.  Drug, patient, and physician characteristics associated with off-label prescribing in primary care.

Authors:  Tewodros Eguale; David L Buckeridge; Nancy E Winslade; Andrea Benedetti; James A Hanley; Robyn Tamblyn
Journal:  Arch Intern Med       Date:  2012-05-28

4.  Chronic conditions and major depression in community-dwelling older adults.

Authors:  Kirsten M Fiest; Shawn R Currie; Jeanne V A Williams; Jianli Wang
Journal:  J Affect Disord       Date:  2010-12-18       Impact factor: 4.839

5.  Utilization of antidepressants in Taiwan: a nationwide population-based survey from 2000 to 2009.

Authors:  Chi-Shin Wu; Wen-Yi Shau; Hung-Yu Chan; Yen-Chieh Lee; Yun-Ju Lai; Mei-Shu Lai
Journal:  Pharmacoepidemiol Drug Saf       Date:  2012-04-17       Impact factor: 2.890

Review 6.  Future directions in vulnerability to depression among youth: integrating risk factors and processes across multiple levels of analysis.

Authors:  Benjamin L Hankin
Journal:  J Clin Child Adolesc Psychol       Date:  2012-08-17

7.  Prevalence, severity, and unmet need for treatment of mental disorders in the World Health Organization World Mental Health Surveys.

Authors:  Koen Demyttenaere; Ronny Bruffaerts; Jose Posada-Villa; Isabelle Gasquet; Viviane Kovess; Jean Pierre Lepine; Matthias C Angermeyer; Sebastian Bernert; Giovanni de Girolamo; Pierluigi Morosini; Gabriella Polidori; Takehiko Kikkawa; Norito Kawakami; Yutaka Ono; Tadashi Takeshima; Hidenori Uda; Elie G Karam; John A Fayyad; Aimee N Karam; Zeina N Mneimneh; Maria Elena Medina-Mora; Guilherme Borges; Carmen Lara; Ron de Graaf; Johan Ormel; Oye Gureje; Yucun Shen; Yueqin Huang; Mingyuan Zhang; Jordi Alonso; Josep Maria Haro; Gemma Vilagut; Evelyn J Bromet; Semyon Gluzman; Charles Webb; Ronald C Kessler; Kathleen R Merikangas; James C Anthony; Michael R Von Korff; Philip S Wang; Traolach S Brugha; Sergio Aguilar-Gaxiola; Sing Lee; Steven Heeringa; Beth-Ellen Pennell; Alan M Zaslavsky; T Bedirhan Ustun; Somnath Chatterji
Journal:  JAMA       Date:  2004-06-02       Impact factor: 56.272

8.  National patterns in antidepressant medication treatment.

Authors:  Mark Olfson; Steven C Marcus
Journal:  Arch Gen Psychiatry       Date:  2009-08

9.  Global burden of depressive disorders in the year 2000.

Authors:  T B Ustün; J L Ayuso-Mateos; S Chatterji; C Mathers; C J L Murray
Journal:  Br J Psychiatry       Date:  2004-05       Impact factor: 9.319

10.  Gender and self-reported mental health problems: predictors of help seeking from a general practitioner.

Authors:  D Tedstone Doherty; Y Kartalova-O'Doherty
Journal:  Br J Health Psychol       Date:  2009-06-12
View more
  10 in total

1.  Psychiatric Epidemiology: It Is About Much More Than Prevalence.

Authors:  Scott B Patten
Journal:  Can J Psychiatry       Date:  2015-12       Impact factor: 4.356

Review 2. 

Authors:  Ai-Leng Foong; Kelly A Grindrod; Tejal Patel; Jamie Kellar
Journal:  Can Fam Physician       Date:  2018-10       Impact factor: 3.275

Review 3.  Demystifying serotonin syndrome (or serotonin toxicity).

Authors:  Ai-Leng Foong; Kelly A Grindrod; Tejal Patel; Jamie Kellar
Journal:  Can Fam Physician       Date:  2018-10       Impact factor: 3.275

Review 4.  Information for mental health systems: an instrument for policy-making and system service quality.

Authors:  A Lora; A Lesage; S Pathare; I Levav
Journal:  Epidemiol Psychiatr Sci       Date:  2016-10-26       Impact factor: 6.892

5.  Global prevalence of antidepressant drug utilization in the community: protocol for a systematic review.

Authors:  Carlotta Lunghi; Michèle Dugas; Jacinthe Leclerc; Elisabetta Poluzzi; Cathy Martineau; Valérie Carnovale; Théo Stéfan; Patrick Blouin; Johanie Lépine; Laura Jalbert; Nataly R Espinoza Suarez; Olha Svyntozelska; Marie-Pier Dery; Giraud Ekanmian; Daniele Maria Nogueira; Pelumi Samuel Akinola; Stéphane Turcotte; Becky Skidmore; Annie LeBlanc
Journal:  BMJ Open       Date:  2022-05-31       Impact factor: 3.006

6.  Effects of the Proton Pump Inhibitors Omeprazole and Pantoprazole on the Cytochrome P450-Mediated Metabolism of Venlafaxine.

Authors:  Maxim Kuzin; Georgios Schoretsanitis; Ekkehard Haen; Benedikt Stegmann; Christoph Hiemke; Gerhard Gründer; Michael Paulzen
Journal:  Clin Pharmacokinet       Date:  2018-06       Impact factor: 6.447

7.  Prevalence of and associations with agitation in residents with dementia living in care homes: MARQUE cross-sectional study.

Authors:  Gill Livingston; Julie Barber; Louise Marston; Penny Rapaport; Deborah Livingston; Sian Cousins; Sarah Robertson; Francesca La Frenais; Claudia Cooper
Journal:  BJPsych Open       Date:  2017-07-27

Review 8.  Factors influencing the development of primary care data collection projects from electronic health records: a systematic review of the literature.

Authors:  Marie-Line Gentil; Marc Cuggia; Laure Fiquet; Camille Hagenbourger; Thomas Le Berre; Agnès Banâtre; Eric Renault; Guillaume Bouzille; Anthony Chapron
Journal:  BMC Med Inform Decis Mak       Date:  2017-09-25       Impact factor: 2.796

9.  Prevalence and Determinants of Long-Term Utilization of Antidepressant Drugs: A Retrospective Cohort Study.

Authors:  Carlotta Lunghi; Ippazio Cosimo Antonazzo; Sofia Burato; Emanuel Raschi; Violetta Zoffoli; Emanuele Forcesi; Elisa Sangiorgi; Marco Menchetti; Pasquale Roberge; Elisabetta Poluzzi
Journal:  Neuropsychiatr Dis Treat       Date:  2020-05-07       Impact factor: 2.570

Review 10.  'Big data' in mental health research: current status and emerging possibilities.

Authors:  Robert Stewart; Katrina Davis
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2016-07-27       Impact factor: 4.328

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.